The estimated Net Worth of James R Neal is at least $2.91 Million dollars as of 15 July 2022. Mr. Neal owns over 25,000 units of XOMA Royalty stock worth over $998,613 and over the last 11 years he sold XOMA stock worth over $428,950. In addition, he makes $1,479,560 as Chief Executive Officer and Director at XOMA Royalty.
James has made over 24 trades of the XOMA Royalty stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 25,000 units of XOMA stock worth $100,750 on 15 July 2022.
The largest trade he's ever made was exercising 53,450 units of XOMA Royalty stock on 21 March 2022 worth over $215,404. On average, James trades about 7,474 units every 80 days since 2014. As of 15 July 2022 he still owns at least 36,822 units of XOMA Royalty stock.
You can see the complete history of Mr. Neal stock trades at the bottom of the page.
James R. Neal serves as Chief Executive Officer, Director of the Company. He was appointed Chief Executive Officer in December 2016 after serving as our Senior Vice President and Chief Operating Officer. He joined the Company in 2009 as its Vice President, Business Development. Mr. Neal brings more than 25 years’ experience forming and maximizing business and technology collaborations globally and in bringing novel products and technologies to market. Prior to joining XOMA, Mr. Neal was Acting Chief Executive Officer of Entelos, Inc. a leading biosimulation company. Previously in 2007, Entelos acquired Iconix Biosciences, a privately held company where Mr. Neal served as Chief Executive Officer and established multi-year collaborations with Bristol-Myers Squibb, Abbott Labs, Eli Lilly and the U.S. Food and Drug Administration. While Executive Vice President of Incyte Genomics from 1999 to 2002, he led the global commercial activities with pharmaceutical company collaborators and partners including Pfizer, Aventis and Schering-Plough, as well as sales, marketing and business development activities for the company. Earlier, he was associated with Monsanto Company in positions of increasing responsibility. Mr. Neal also serves on the Board of Directors of Leading Biosciences Inc. Mr. Neal earned his B.S. in Biology and his M.S. in Genetics and Plant Breeding from the University of Manitoba, Canada, and holds an Executive MBA degree from Washington University in St. Louis, Missouri. Mr. Neal has significant experience with biopharmaceutical companies and brings the unique perspective of the Chief Executive Officer of the Company to the Board.
As the Chief Executive Officer and Director of XOMA Royalty, the total compensation of James Neal at XOMA Royalty is $1,479,560. There are no executives at XOMA Royalty getting paid more.
James Neal is 64, he's been the Chief Executive Officer and Director of XOMA Royalty since 2016. There are 3 older and 4 younger executives at XOMA Royalty. The oldest executive at XOMA Royalty Corp. is W. Denman Van Ness, 77, who is the Independent Chairman of the Board.
James's mailing address filed with the SEC is C/O XOMA CORPORATION, 2200 POWELL STREET, SUITE 310, EMERYVILLE, CA, 94608.
Over the last 21 years, insiders at XOMA Royalty have traded over $74,428,857 worth of XOMA Royalty stock and bought 6,217,869 units worth $44,091,555 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog..., and Bros. Advisors Lp667, L.P.B.... On average, XOMA Royalty executives and independent directors trade stock every 31 days with the average trade being worth of $3,397,377. The most recent stock trade was executed by Owen Hughes on 2 October 2023, trading 1,000 units of XOMA stock currently worth $13,830.
xoma has an extensive portfolio of products, programs, and technologies that are the subject of licenses the company has in place with other biotech and pharmaceutical companies. many of these licenses are the result of the company's pioneering efforts in the discovery and development of antibody therapeutics. there are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. in order to maximize its value in a licensing transaction, xoma continues to invest in x358, an allosteric monoclonal antibody that reduces insulin receptor activity, as the antibody could have a major impact on the treatment of hyperinsulinism. for more information, visit www.xoma.com.
XOMA Royalty executives and other stock owners filed with the SEC include: